DEVELOPING TOMORROW’S CANCER THERAPIES. TODAY.

Corporate profile

  • Private – spin-out from APEIRON Biologics AG
  • Launched in January 2022
  • Based in Vienna, Austria
  • Highly experienced management team with strong scientific and capital markets expertise
  • In-house acumen in discovery, development, clinical, CMC and financial operations
  • Targeting funding round in H2 2022

Investment case: Excellent basis for future value growth

  • Innovative IO-focused operations
    • Unencumbered IO projects
  • Proprietary EPiC cell-therapy platform
    • Short treatment times in out-patient setting
    • Uses the patient’s fresh immune cells
    • Validated, safe, optimized process
  • Clinical stage lead candidate APN401
  • Immune-reactive small molecule project for oral application
  • In-house Innovation Hub driving long-term pipeline growth

Innovative immuno-oncology pipeline

Why are we targeting Cbl-b?

  • Modulating Cbl-b is central to fighting tumor cells in a broad range of tumor indications
  • Cbl-b is involved in several negative regulatory pathways
  • Cbl-b deficiency activates a variety of immune cells for tumor destruction

Lead clinical program APN401: first-in-class Cbl-b silencing

  • Robust pre-clinical data
  • First-in-human trial (single & multiple dose)
    • APN401 was safe and well tolerated; first signs of clinical efficacy
  • Ongoing Phase 1b multi-center study in solid tumors:
    • Dose level 1 and 2 completed (safe and well tolerated)
    • Dose level 3 ongoing
    • First confirmation of enhanced anti-tumor immunity (DL 1)

EPiC – our GMP-certified cell-therapy platform

  • Patient-centric – short treatment times (<24 hours) in out-patient setting
  • Uses patient’s own fresh immune cells
  • Multiple targets (e.g., siRNA, mRNA)
  • Multiple treatment options (no freezing necessary)

Key differentiators vs conventional cell therapies

For further information, please visit our main website:

Innovative immuno-oncology pipeline

TargetsProjectsEARLY STAGECLINICAL
DISCOVERYPRECLINICALPHASE 1PHASE 2PHASE 3
Cbl-b
via
EPiC
APN401
autologous cell therapy targeting Cbl-b
first-in-human trial completed
INV441
adoptive cell therapy – TIL activation in solid tumors
Novel IO targetsINV501
oral application for tumor-specific immune activation

Why are we targeting Cbl-b?

  • Modulating Cbl-b is central to fighting tumor cells in a broad range of tumor indications
  • Cbl-b is involved in several negative regulatory pathways
  • Cbl-b deficiency activates a variety of immune cells for tumor destruction

Lead clinical program APN401: first-in-class Cbl-b silencing

  • Robust pre-clinical data
  • First-in-human trial (single & multiple dose)
    • APN401 was safe and well tolerated; first signs of clinical efficacy
  • Ongoing Phase 1b multi-center study in solid tumors:
    • Dose level 1 and 2 completed (safe and well tolerated)
    • Dose level 3 ongoing
    • First confirmation of enhanced anti-tumor immunity (DL 1)

EPiC – our GMP-certified cell-therapy platform

  • Patient-centric – short treatment times (<24 hours) in out-patient setting
  • Uses patient’s own fresh immune cells
  • Multiple targets (e.g., siRNA, mRNA)
  • Multiple treatment options (no freezing necessary)

Key differentiators vs conventional cell therapies

For further information, please visit our main website: